To address this lack of knowledge, we recently uncovered a novel mechanism by which PDACs with KRAS and TP53 mutations (a combination found in most PDACs) promote cancer pathogenesis via modified splicing of GTPase-activating protein (GAP) mRNAs and subsequent amplification of KRAS signaling [32]. This evidence concerns the gene KRAS and cancer.